FDA Names Elizabeth Jungman Head of Regulatory Policy

The U.S. Food and Drug Administration (FDA) has selected Elizabeth Jungman, JD, MPH, to serve as the head of the FDA’s Office of Regulatory Policy, according to STAT. Ms. Jungman currently directs the public health programs at Pew Charitable Trusts, where she has overseen initiatives related to the safety of prescription drugs, over-the-counter medicines, and other consumer health-care products.

Ms. Jungman will begin her tenure at the FDA’s Office of Regulatory Policy this summer. This office falls within the agency’s Center for Drug Evaluation and Research and is responsible for managing the development of new guidelines and policies for regulating human drugs, such as reining in abuses of the FDA’s safety systems.

In her position at Pew, Ms. Jungman worked closely with the FDA, and she serves on the agency’s Pharmacy Compounding Advisory Committee. She also worked as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions; in this role, she helped draft and negotiate the FDA Safety and Innovation Act of 2012, as well as other health- and drug-related legislation.

Source: STAT, April 24, 2019.